Analysts expect Apricus Biosciences Inc (NASDAQ:APRI) to post earnings of ($0.17) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Apricus Biosciences’ earnings. Apricus Biosciences reported earnings per share of ($0.80) in the same quarter last year, which indicates a positive year-over-year growth rate of 78.8%. The business is expected to report its next earnings report on Thursday, August 3rd.
According to Zacks, analysts expect that Apricus Biosciences will report full-year earnings of ($0.79) per share for the current fiscal year. For the next fiscal year, analysts expect that the business will report earnings of $1.50 per share. Zacks’ EPS averages are an average based on a survey of sell-side research analysts that follow Apricus Biosciences.
Apricus Biosciences (NASDAQ:APRI) last posted its quarterly earnings data on Thursday, May 11th. The company reported $1.04 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.25 by $0.21. During the same quarter in the prior year, the business posted ($0.50) EPS.
Separately, Rodman & Renshaw started coverage on Apricus Biosciences in a report on Wednesday, April 26th. They issued a “buy” rating on the stock.
TRADEMARK VIOLATION WARNING: “-$0.17 Earnings Per Share Expected for Apricus Biosciences Inc (APRI) This Quarter” was originally reported by sleekmoney and is the property of of sleekmoney. If you are reading this news story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this news story can be read at https://sleekmoney.com/0-17-earnings-per-share-expected-for-apricus-biosciences-inc-apri-this-quarter/1893480.html.
Several institutional investors have recently added to or reduced their stakes in APRI. Anson Funds Management LP acquired a new position in Apricus Biosciences during the third quarter worth $1,723,000. Sarissa Capital Management LP acquired a new position in Apricus Biosciences during the fourth quarter worth $1,882,000. Finally, Vanguard Group Inc. raised its position in Apricus Biosciences by 115.6% in the first quarter. Vanguard Group Inc. now owns 341,333 shares of the company’s stock worth $720,000 after buying an additional 182,991 shares during the period.
Apricus Biosciences (NASDAQ:APRI) traded up 25.56% during mid-day trading on Thursday, hitting $1.13. 2,336,388 shares of the stock were exchanged. The company has a market capitalization of $14.43 million, a PE ratio of 2.54 and a beta of 0.26. The stock has a 50 day moving average price of $1.08 and a 200 day moving average price of $1.80. Apricus Biosciences has a 1-year low of $0.86 and a 1-year high of $5.95.
About Apricus Biosciences
Apricus Biosciences, Inc is a pharmaceutical company, which develops pharmaceutical products. The Company primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company’s drug delivery technology is a permeation enhancer called NexACT.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/0-17-earnings-per-share-expected-for-apricus-biosciences-inc-apri-this-quarter/1893480.html
Receive News & Ratings for Apricus Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apricus Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.